Search Results - Piétro Scalfaro

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replicationin vitro

    The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replicationin vitro by Jan Paeshuyse, Artur Kaul, Erik De Clercq, Brigitte Rosenwirth, Jean‐Maurice Dumont, Piétro Scalfaro, Ralf Bartenschlager, Johan Neyts

    Published 2006
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice<i>in vivo</i>

    Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice<i>in vivo</i> by Kazuaki Inoue, Takuya Umehara, Urs T. Rüegg, Fumihiko Yasui, Tsunamasa Watanabe, Hiroshi Yasuda, Jean‐Maurice Dumont, Piétro Scalfaro, Makoto Yoshiba, Michinori Kohara

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study

    Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study by Robin Erken, Patrice André, Élise Roy, Neeltje A. Kootstra, Noélie Barzic, Hugo Girma, Christian Laveille, Pauline Radreau‐Pierini, Raphaël Darteil, Jacky Vonderscher, Piétro Scalfaro, Pisit Tangkijvanich, Robert Flisiak, H. W. Reesink

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

    The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients by Robert Flisiak, S.V. Feinman, Maciej Jabłkowski, Andrzej Horban, Wiesław Kryczka, Małgorzata Pawłowska, Jenny Heathcote, G. Mazzella, C. Vandelli, Valerie Nicolas‐Métral, Pierre Grosgurin, Jorge S. Liz, Piétro Scalfaro, Hervé Porchet, R. Crabbé

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH

    Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH by Vlad Ratziu, Stephen A. Harrison, V. Loustaud‐Ratti, Christophe Bureau, Eric Lawitz, Manal F. Abdelmalek, Naim Alkhouri, Sven Francque, Hugo Girma, Raphaël Darteil, Harold Couchoux, Myles Wolf, Arun J. Sanyal, Jacky Vonderscher, Piétro Scalfaro

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent

    Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent by Roger G. Ptak, Philippe Gallay, Dirk Jochmans, Andrew P. Halestrap, Urs T. Rüegg, Luke A. Pallansch, Michael Bobardt, Marie‐Pierre de Béthune, Johan Neyts, Erik De Clercq, Jean‐Maurice Dumont, Piétro Scalfaro, Kamel Besseghir, Roland M. Wenger, Brigitte Rosenwirth

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: